retiredpharma

Celldex Therapeutics: Plenty of Cash, Pending Clinical Catalysts

Mike,

I read you often and I am a bio-pharma investor! Bought Avant before the CLDX merger about 13 and sold all into the August 2008 run-up at 17-18! Got back in a bit early but average cost of shares is about 7 even w/ this bad recent downturn.

I believe in the science of CLDX but like many I am questioning the silence from management. Not sure if this is a legal thing w/ the CRGN merger but now that the merger is behind us it seems to persist!

I want to double down now and probably will no matter but would like your thoughts on this Transparency Issue...real or imagined?

retiredpharma